Healthcare

Bio-technologies

Diagnostics

Medical devices & equipments

Medical services

  • Zhejiang Hisoar Pharmaceutical Co., Ltd.

    Trade Code: 002099

    Global leading supplier of Clindamycin and other API, 90% for export, 50% market shares in the world. Fosun Chemical Investment: 2003. IPO on December 26, 2006 on the ShenZhen Stock Exchange, trade code: 002099. 

    Website: http://www.hisoar.com

  • Changzhou Bioregen Biopharmaceutical Co., Ltd

    Bioregen is an innovative biomaterial firm with unique sodium hyaluronate technology platform, providing international-leading solutions for postoperative adhesions, especially for gynecologic surgeries. Three anti-adhesion products have been launched and are highly recognized by globally top clinical experts. Principle Fund III Investment: 2016.

    Website: http://www.bioregenmed.com

  • Shanghai Genechem Co., Ltd

    Genechem is one of the leading disease key gene diagnosis and treatment providers, and the largest RNA interference and lentivirus research service provider in China. Principle Fund III Investment: 2014.

    Website: http://www.genechem.com.cn

  • Genesky Technologies (Suzhou) Inc.

    Genesky is a fast-growing biotech firm with innovative gene detecting technology. It provides efficient, low-cost gene detecting products to pregnant couples and newborn babies. Principle Fund III Investment: 2015.

    Website: http://www.geneskies.com

  • Amicogen (China) Biopharm Co., Ltd.

    A leading supplier of pharmaceutical raw materials and special resins for ion exchange, absorbents and special applications for worldwide markets. Amicogen develops and manufactures API, intermediate and fine chemicals in accordance with related GMP.Principle Fund III Investment: 2016.

    Website: http://www.lksz.cn

  • Zhejiang Hisoar Pharmaceutical Co., Ltd.

    Trade Code: 002099

    Global leading supplier of Clindamycin and other API, 90% for export, 50% market shares in the world. Fosun Chemical Investment: 2003. IPO on December 26, 2006 on the ShenZhen Stock Exchange, trade code: 002099. 

    Website: http://www.hisoar.com

  • Amicogen (China) Biopharm Co., Ltd.

    A leading supplier of pharmaceutical raw materials and special resins for ion exchange, absorbents and special applications for worldwide markets. Amicogen develops and manufactures API, intermediate and fine chemicals in accordance with related GMP.Principle Fund III Investment: 2016.

    Website: http://www.lksz.cn

  • Genesky Technologies (Suzhou) Inc.

    Genesky is a fast-growing biotech firm with innovative gene detecting technology. It provides efficient, low-cost gene detecting products to pregnant couples and newborn babies. Principle Fund III Investment: 2015.

    Website: http://www.geneskies.com

  • Shanghai Genechem Co., Ltd

    Genechem is one of the leading disease key gene diagnosis and treatment providers, and the largest RNA interference and lentivirus research service provider in China. Principle Fund III Investment: 2014.

    Website: http://www.genechem.com.cn

  • Changzhou Bioregen Biopharmaceutical Co., Ltd

    Bioregen is an innovative biomaterial firm with unique sodium hyaluronate technology platform, providing international-leading solutions for postoperative adhesions, especially for gynecologic surgeries. Three anti-adhesion products have been launched and are highly recognized by globally top clinical experts. Principle Fund III Investment: 2016.

    Website: http://www.bioregenmed.com